LYMPHANGIOLEIOMYOMATOSIS (LAM)
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS (LAM) explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS (LAM) trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS (LAM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Leukemia drug tested as new hope for rare lung disease
Disease control Recruiting nowThis study is testing whether a drug called imatinib, already approved for leukemia, is safe for longer-term use in people with a rare lung disease called LAM. It will involve 20 women with LAM who will take either imatinib or a placebo for six months. The main goal is to check f…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Apr 02, 2026 00:42 UTC
-
Scientists hunt for blood clues to track rare lung disease
Knowledge-focused Recruiting nowThis study aims to understand if tiny particles in the blood, called extracellular vesicles, can serve as useful markers for a rare lung disease called LAM. Researchers will collect blood samples and health data from 80 women with LAM, a related condition called TSC, and healthy …
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC